These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8404092)

  • 1. Phenotypes and lymphokine-activated killer activity of pleural cavity lymphocytes of lung cancer patients without malignant effusion.
    Takahashi K; Sone S; Kimura S; Ogura T; Monden Y
    Chest; 1993 Jun; 103(6):1732-8. PubMed ID: 8404092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphokine-activated killer induction and its regulation by macrophages in malignant pleural effusions.
    Yanagawa H; Sone S; Nii A; Fukuta K; Nakanishi M; Maeda K; Honda M; Ogura T
    Jpn J Cancer Res; 1989 Dec; 80(12):1220-7. PubMed ID: 2516849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from pleural cavity mononuclear cells of lung cancer patients without malignant effusion.
    Takahashi K; Sone S; Saito S; Kamamura Y; Uyama T; Ogura T; Monden Y
    Jpn J Cancer Res; 1995 Sep; 86(9):861-6. PubMed ID: 7591964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells].
    Guo Y; Xing Z
    Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):80-2, 127. PubMed ID: 7553955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte/macrophage-colony-stimulating factor augments lymphokine-activated killer activity from lymphocytes via macrophages in lung cancer patients.
    Takahashi K; Saito S; Kamamura Y; Katakawa M; Monden Y
    Cancer Immunol Immunother; 2000 Dec; 49(10):537-43. PubMed ID: 11129324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-2-inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients.
    Sone S; Kunishige E; Fawzy F; Yanagawa H; Nii A; Maeda K; Atagi S; Heike Y; Nishioka Y; Mizuno K
    Jpn J Cancer Res; 1991 Jun; 82(6):716-23. PubMed ID: 1649813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of the cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells.
    Guo YS; Xing ZL
    Chin Med J (Engl); 1994 Dec; 107(12):903-5. PubMed ID: 7882727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gamma-interferon enhances the cytotoxic activity of interleukin-2-induced peripheral blood lymphocyte (LAK) cells, tumor infiltrating lymphocytes (TIL), and effusion associated lymphocytes.
    Papamichail M; Baxevanis CN
    J Chemother; 1992 Dec; 4(6):387-93. PubMed ID: 1287141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphokine-activated killer cytotoxicity and lymphocyte subpopulations in patients with acute leukemia.
    Parrado A; Casares S; Rodríguez-Fernández JM
    Leuk Res; 1994 Nov; 18(11):815-22. PubMed ID: 7526078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OK-432 develops CTL and LAK activity in mononuclear cells from regional lymph nodes of lung cancer patients.
    Takahashi K; Harauchi D; Kimura S; Saito S; Monden Y
    Int J Immunopharmacol; 1998 Aug; 20(8):375-88. PubMed ID: 9778099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells.
    Miyazaki K; Yasumoto K; Yano T; Matsuzaki G; Sugimachi K; Nomoto K
    Cancer Res; 1991 Oct; 51(19):5261-5. PubMed ID: 1833049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross regulation by IL-10 and IL-2/IL-12 of the helper T cells and the cytolytic activity of lymphocytes from malignant effusions of lung cancer patients.
    Chen YM; Yang WK; Ting CC; Tsai WY; Yang DM; Whang-Peng J; Perng RP
    Chest; 1997 Oct; 112(4):960-6. PubMed ID: 9377959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16- CD56- large granular lymphocyte LAK cells.
    Roussel E; Gerrard JM; Greenberg AH
    Clin Exp Immunol; 1990 Nov; 82(2):416-21. PubMed ID: 1700746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmented human-tumor-cytolytic activity of peripheral blood lymphocytes and cells from a mixed lymphocyte/tumor culture activated by interleukin-12 plus interleukin-2, and the phenotypic characterization of the cells in patients with advanced carcinoma.
    Koyama S
    J Cancer Res Clin Oncol; 1997; 123(9):478-84. PubMed ID: 9341896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphokine-activated killer (LAK) cell activity in tumor-infiltrating lymphocytes from non-small cell lung cancer.
    Pisani RJ; Krco CJ; Wold LE; McKean DJ
    Am J Clin Pathol; 1989 Oct; 92(4):435-46. PubMed ID: 2552792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The intrapleural administration of recombinant interleukin-2 (rIL-2) to patients with malignant pleural effusion: clinical trials.
    Suzuki H; Abo S; Kitamura M; Hashimoto M; Izumi K
    Surg Today; 1993; 23(12):1053-9. PubMed ID: 8118118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
    Fujioka T; Nomura K; Hasegawa M; Ishikura K; Kubo T
    Br J Urol; 1994 Jan; 73(1):23-31. PubMed ID: 8298895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The characterization of peritoneal and pleural exudate cells from malignant effusions.
    Oka M; Yoshino S; Hazama S; Shimoda K; Suzuki T
    Surg Today; 1993; 23(6):500-3. PubMed ID: 8102920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effector function of lymphokine-activated killer cells and cytotoxic T lymphocytes in ovarian epithelial carcinoma.
    Lentz SS; Kovach JS; McKean DJ; Wieand HS; Podratz KC
    Gynecol Oncol; 1990 Aug; 38(2):191-6. PubMed ID: 2387535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer (NK) and lymphokine-activated killer (LAK) activities in a patient who recovered from cancer, and the characteristics of LAK cells generated from CD4-CD8- and CD8+ peripheral blood lymphocytes.
    Komatsu F; Kihara K
    Clin Immunol Immunopathol; 1995 Oct; 77(1):75-81. PubMed ID: 7554487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.